Financial Data and Key Metrics Changes - In 2025, SIGA reported product revenues of approximately $88 million, which includes $53 million from oral TPOXX, $26 million from IV TPOXX, and $6 million from international oral TPOXX sales [3][10] - The company achieved a pretax operating income of approximately $24 million and a net income of approximately $23 million for the year [10][11] - The fully diluted income per share for 2025 was $0.32, and the company maintained a strong cash balance of approximately $155 million with no debt [11] Business Line Data and Key Metrics Changes - The primary revenue driver for SIGA in 2025 was product deliveries to the U.S. Strategic National Stockpile (SNS) under the BARDA contract, which accounted for the majority of product revenues [10] - The company secured $27 million in funding to support pediatric formulation development and IV technology transfer efforts, reinforcing the role of TPOXX in biothreat preparedness [4] Market Data and Key Metrics Changes - SIGA has approximately $26 million in outstanding U.S. government orders related to the IV TPOXX procurement order, expected to be delivered in 2026 [4][11] - A recent $13 million order from a country in the Asia-Pacific region indicates ongoing international engagement and demand for TPOXX [6][21] Company Strategy and Development Direction - SIGA remains focused on supporting global governments in preparedness strategies for biological threats, particularly smallpox, and aims to be a leading provider of antiviral treatments [2][3] - The company emphasizes strategic stockpiling as foundational to preparedness and continues discussions with various potential customers globally [6][21] - SIGA is open to pursuing acquisitions or in-licensing opportunities to broaden its pipeline while maintaining a disciplined and strategic approach [18] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of readiness in the face of heightened geopolitical risks and biological threats, asserting that TPOXX's established safety profile makes it suitable for emergency situations [3] - The company expects the European Medicines Agency (EMA) to confirm the positive benefit-risk balance of Tecovirimat SIGA for smallpox treatment, with a recommendation expected in March [7][8] - SIGA entered 2026 from a position of strength, focusing on financial discipline and long-term value creation [9] Other Important Information - The company is actively engaged with the U.S. government and key stakeholders regarding future procurement contracts, indicating ongoing productive discussions [4][15] - SIGA's pricing and manufacturing approach aligns with U.S. government priorities, ensuring the lowest prices for TPOXX as the largest customer [5] Q&A Session Summary Question: Update on the timing of the next U.S. government RFP for TPOXX - Management indicated that smallpox preparedness remains a focus for the U.S. government, but no specific timing details for the next RFP were available [15][16] Question: Capital allocation priorities looking ahead - Management stated that capital management will remain disciplined and flexible, with no immediate updates on special cash dividends [17] Question: Openness to acquisitions or in-licensing opportunities - Management confirmed that the company is open to pursuing acquisitions or in-licensing opportunities while maintaining a strategic focus [18] Question: Details on the recent $13 million TPOXX order - Management noted that the order reflects progress in strengthening relationships with government partners, but specific details about the contract could not be disclosed for security reasons [21][22]